- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Vor Biopharma Inc (VOR)
Vor Biopharma Inc stock price live, this page displays NASDAQ VOR stock exchange data. View the VOR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Vor Biopharma Inc real time stock price chart below.
What Is the Vor Biopharma Inc Stock Price Today?
The Vor Biopharma Inc stock price today is 2.210.
What Is the Stock Symbol for Vor Biopharma Inc?
The stock symbol for Vor Biopharma Inc is "VOR."
What Stock Exchange Does Vor Biopharma Inc Trade On?
Vor Biopharma Inc is listed and trades on the NASDAQ stock exchange.
Is Vor Biopharma Inc a Good Stock to Buy?
Determining whether Vor Biopharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VOR quote. (ISIN: US9290331084)
What Is the Vor Biopharma Inc Stock Price Today?
The Vor Biopharma Inc stock price today is 2.210.
What Is the Stock Symbol for Vor Biopharma Inc?
The stock symbol for Vor Biopharma Inc is "VOR."
What Stock Exchange Does Vor Biopharma Inc Trade On?
Vor Biopharma Inc is listed and trades on the NASDAQ stock exchange.
Is Vor Biopharma Inc a Good Stock to Buy?
Determining whether Vor Biopharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VOR quote. (ISIN: US9290331084)
NASDAQ
Currency in USD
2.210
-0.170(-7.14%)
Closed·
After Hours
2.250+0.040(+1.81%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.200
2.490
52 wk Range
0.131
3.290
VOR Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
VOR is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.2002.490
52 wk Range
0.1313.290
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VOR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Neutral
Price Target
1.175
Downside
-46.83%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Vor Biopharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Vor Bio appoints Sandy Mahatme as CFO and CBO
- Investing.com
- Vor Bio appoints Sandy Mahatme as CFO and CBO
- Investing.com
- Vor Biopharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Vor Biopharma Company Profile
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Vor Biopharma Inc SWOT Analysis
AML Breakthrough | Vor Biopharma's trem-cel + Mylotarg combo shows promise in improving relapse-free survival for AML patients, with key data expected in 2025 |
Financial Runway | $91.9M cash position and $56M PIPE extend operations into Q1 2026, supporting critical clinical milestones despite negative EPS forecasts |
Market Potential | Analyst price targets range from $5 to $18, reflecting significant upside potential in the competitive oncology therapeutics landscape |
Strategic Expansion | Explore Vor's plans for a pivotal two-year controlled trial and potential applications of its technology beyond AML, diversifying its pipeline |
Compare VOR to Peers and Sector
Metrics to compare | VOR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVORPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.3x | −2.3x | −0.5x | |
PEG Ratio | −0.12 | −0.03 | 0.00 | |
Price/Book | 4.2x | 1.2x | 2.6x | |
Price / LTM Sales | - | 71.4x | 3.2x | |
Upside (Analyst Target) | −68.3% | 242.9% | 44.3% | |
Fair Value Upside | Unlock | 14.0% | 6.6% | Unlock |
Analyst Ratings
1 Buy
4 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 1.175
(-46.83% Downside)
Earnings
Latest Release
May 08, 2025
EPS / Forecast
-0.26 / -0.2517
Revenue / Forecast
-- / --
FAQ
What Is the Vor Biopharma (VOR) Stock Price Today?
The Vor Biopharma stock price today is 2.21.
What Stock Exchange Does Vor Biopharma Trade On?
Vor Biopharma is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Vor Biopharma?
The stock symbol for Vor Biopharma is "VOR."
What Is the Vor Biopharma Market Cap?
As of today, Vor Biopharma market cap is 276.16M.
What Is Vor Biopharma's Earnings Per Share (TTM)?
The Vor Biopharma EPS (TTM) is -1.43.
When Is the Next Vor Biopharma Earnings Date?
Vor Biopharma will release its next earnings report on 06 Aug 2025.
From a Technical Analysis Perspective, Is VOR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Vor Biopharma Stock Split?
Vor Biopharma has split 0 times.
How Many Employees Does Vor Biopharma Have?
Vor Biopharma has 159 employees.
What is the current trading status of Vor Biopharma (VOR)?
As of 19 Jul 2025, Vor Biopharma (VOR) is trading at a price of 2.21, with a previous close of 2.38. The stock has fluctuated within a day range of 2.20 to 2.49, while its 52-week range spans from 0.13 to 3.29.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.